NeOnc Technologies is developing a novel approach to treat aggressive brain cancers, such as glioblastoma, by using intranasal drug delivery to bypass the blood-brain barrier. The drug, NEO100, is based on perillyl alcohol (POH) and has shown promising results in clinical trials. NeOnc initially aimed for a traditional IPO but is now pursuing a direct listing to go public. While direct listings are rare in biotech, they can be beneficial for well-capitalized companies. NeOnc plans to continue developing other programs using NEO100 and hopes to advance its Phase 2a test for glioblastoma by mid-2025.
Source link
A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets
